NASDAQ StockHansen Natural CpHansen Natural Corporation was incorporated in Delaware on April 25, 1990. Its principal place of business is at 1010 Railroad Street, Corona, California 92882 and its telephone number is (951) 739-6200. When this report uses the words "Hansen", "HBC", "the Company", "we", "us", and "our", these words refer to Hansen Natural Corporation and our subsidiaries other than Monster ... moreTeva Pharm Ind, Inc AdrLigand PharmWe are an early-stage biotech company that focuses on discovering and developing new drugs that address critical unmet medical needs in the areas of thrombocytopenia, cancer, hepatitis C, hormone-related diseases, osteoporosis and inflammatory diseases. We strive to develop drugs that are more effective and/or safer than existing therapies, that are more ... moreIllumina, IncBiogen Idec, IncUal CorpElectronic Arts In-home video game players (such as the Sony PlayStation ® 2, Microsoft Xbox ® and Xbox 360 tm and Nintendo GameCube tm ) we call these players consoles, Personal computers ... moreOpsware, IncVitesse SemiconductorThe fabrication of integrated circuits is a highly complex and technically demanding process. Defects in designs, problems associated with transitions to newer manufacturing processes and the inadvertent use of defective or contaminated materials can result in unacceptable manufacturing yields and performance. These problems are frequently difficult to detect in the early stages of the ... moreGilead ScienceNutralogix Labs, IncEmdeonUnited Svcs Glbl Inv, Inc Cl AEncysive PharmEncysive Pharmaceuticals Inc. is a global biopharmaceutical company that engages in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs. We focus our research and development programs predominantly on the treatment and prevention of interrelated diseases of the vascular endothelium and ... moreMedicines Co (the)We exclusively licensed Angiomax from Biogen Idec, Inc. in 1997 and we have exclusive license rights to develop, market and sell Angiomax worldwide. We received our first marketing approval from the U.S. Food and Drug Administration, or the FDA, in December 2000 for Angiomax for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous ... more |
Home
| Message boards
| Newsletters
| Latest Comments
| VC directory
| AIM London Stock Exchange
| Canadian stocks
| Chinese stocks
| Broker Directory
© 2007 - 2008 hotstocked.com - All rights reserved.


